NOVARTIS

April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-001562-42/ Novartis Protocol ID CSPP100A2370

A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with an initial 8-week evaluation, followed by a 2-3 year follow-up to compare long-term safety of an aliskiren-based regimen to a ramipril-based regimen in hypertensive patients ≥ 65 years of age.

Trial CSPP100A2370 was cancelled with no patient enrollment and as such, no results will be reported.